The UK Government has accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare, the MHRA announced on 6 October 2026. The response sets out priorities and initial delivery steps; acceptance does not mean every recommendation has already been put into practice.
What the Commission recommended
The Commission’s report, published on 10 September 2026, addresses more than AI medical devices. It considers AI-enabled products used in healthcare, professional responsibilities, provider governance, patient safety and redress, transparency, public confidence and assurance across the health system. Its central proposal is a proportionate approach that accounts for risk and follows products through their lifecycle.
As an Amazon Associate I earn from qualifying purchases.
The Commission gathered evidence over a year from more than 12,000 people, including patients, members of the public, clinicians, healthcare leaders, industry and technology developers, according to the MHRA. That figure describes the programme’s evidence gathering; it is not a poll showing support for each recommendation.
Free tools Windows power users keep installed
One-click scans. No signup required.
What accepting all 44 recommendations means
The Government has accepted the recommendations and described how it intends to deliver them across the UK. Its response points to priorities and planned actions, rather than completed implementation. The approach is intended to make regulation responsive to the level of risk, support safe deployment in real-world settings and clarify responsibilities across the system.
#1 Best Overall
The proposed work includes more navigable regulatory pathways and comparative evidence to help healthcare organisations judge clinical effectiveness and value when considering adoption. It also aims to strengthen monitoring, reporting and learning from how AI performs in practice.
How the plans affect different parts of healthcare
| Area | Government priority or intended effect |
|---|---|
| Healthcare organisations | DHSC and NHS England, working with devolved health departments, are to develop an AI Readiness Toolbox to support organisational readiness and safe deployment. |
| Healthcare workforce | Professional regulators, education bodies and healthcare organisations are expected to support AI literacy and training. |
| Manufacturers, providers, clinicians and regulators | The response seeks clearer responsibilities, alongside stronger reporting, monitoring and learning from real-world use. |
| Patients and the public | The intended direction includes clearer information about AI use and better routes to raise concerns and seek redress if things go wrong. |
| Organisations considering adoption | More navigable regulatory pathways and comparative evidence are intended to help assess clinical effectiveness and value. |
These are stated aims and actions in the Government response, not evidence that the tools, training or routes to redress are already available everywhere. The Government’s explainer describes the intended implications for patients, professionals, providers and developers.
Rank #2
- Book: deep medicine: how artificial intelligence can make healthcare human again
- Language: english
- Binding: hardcover
What happens next for AI medical devices
The response includes specific MHRA steps for AI-enabled medical devices. On 6 October 2026, the MHRA said applications had opened for Phase 3 of its AI Airlock, a regulatory sandbox focused on post-market surveillance and managing devices through their lifecycle. It also said draft guidance on managing changes to AI-enabled medical devices was planned by December 2026, with consultation on qualifying and classifying AI-enabled devices due to begin in 2027. Those dates were future plans as reported on 6 October, not confirmation that the guidance or consultation had since been delivered.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →The AI Airlock and device guidance concern product regulation. They are only part of the Commission’s wider agenda, which also addresses professional practice, provider governance and system-wide assurance. The Government response and the MHRA’s announcement of acceptance set out the commitments.
Rank #3
Why the panel’s remit matters
A device’s regulatory status is not the whole question of how AI should be used in healthcare. Safe use can also depend on how a provider assesses and deploys a system, how clinicians understand their responsibilities, how performance is monitored after deployment and whether patients know when AI is involved. The Commission’s broader remit reflects that chain of responsibilities rather than treating AI regulation as a device-classification issue alone.
Commission co-chairs Professors Alastair Denniston and Henrietta Hughes, both practising NHS doctors, described their vision as “a future healthcare system that is increasingly tech-enabled and always people-centred,” in an MHRA announcement dated 10 September 2026. That is their stated aim for the work, not a finding that the system has already achieved it.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
